U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06922110) titled 'An Open-Label Study of Azetukalner in Major Depressive Disorder' on March 20.
Brief Summary: X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).
Study Start Date: March 18
Study Type: INTERVENTIONAL
Condition:
Major Depressive Disorder
Intervention:
DRUG: Azetukalner
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.
Recruitment Status: ENROLLING_BY_INVITATION...